

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Beta Adrenergic Agents – Long Acting PDL Edit
<b>First Implementation Date:</b>	November 10, 2004
<b>Revised Date:</b>	July 9, 2020
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Long-acting beta-agonists open the airways by relaxing smooth muscle around the airways. They do not decrease inflammation of pulmonary tissues and are often used with inhaled steroids as a long-term control medication to open the airways in people with moderate to severe asthma.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> <li>Serevent® Diskus®</li> </ul>	<ul style="list-style-type: none"> <li>Arcapta® Neohaler®</li> <li>Brovana®</li> <li>Perforomist®</li> <li>Striverdi® Respimat®</li> </ul>

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List  
 Appropriate Indications  Clinical Edit

**Data Sources:**  Only Administrative Databases  Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Beta Adrenergic Agents – Long Acting
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 1 or more preferred agents
  - Documented trial period of preferred agent
  - Documented ADE/ADR to preferred agent

## Denial Criteria

- Lack of adequate trial on required preferred agent
- Therapy will be denied if no approval criteria are met

## Required Documentation

Laboratory Results:   
MedWatch Form:

Progress Notes:   
Other:

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

1 year

## References

1. Evidence-Based Medicine Analysis: "Beta-2 Adrenergic Agonist Agents", UMKC-DIC; December 2019.
2. Evidence-Based Medicine and Fiscal Analysis: "Beta-Adrenergic Agents, Long Acting - Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; January 2020.
3. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2018.
4. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
5. USPDI, Micromedex; 2020.
6. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.

### *SmartPA PDL Proposal Form*

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.